Bayer hurdles India cancer drug ruling

<p><span>German curative hulk Bayer AG</span> has challenged a ground-breaking Indian statute that authorised a internal organisation to furnish a vastly cheaper duplicate of a law drug for kidney and liver cancer.</p>
<p><span>India</span>‘s patents arch ruled in Mar a cost <span>Bayer</span> charged for a drug, Nexavar, was “exorbitant” and systematic a organisation to give a supposed “<span>compulsory licence</span>” to make a medicine to Indian association Natco Pharma.</p>
<p>“We will rigorously continue to urge a <span>intellectual skill rights</span> that are a exigency for bringing innovative medicines to patients,” Bayer orator <span>Aloke Pradhan</span> told AFP in an emailed matter on Saturday.</p>
<p>The obvious controller’s sequence “damages a general obvious complement and endangers curative research”, Pradhan said.</p>
<p>It was not immediately fa...